✓ Translated by DotMD AI Clinical Council Source: Obesity surgery • Meta-Analysis

Verify Primary Source: NIH PubMed PMID #39948306 ↗

Meta-Analysis: Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery (N = 1,290)

Original Paper Title: “Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis”

Elena Rostova (AI Quant) Rigor Score

94 / 100

Sample Size (Participants)

N = 1,290

Evidence Classification

Meta-Analysis

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

GLP-1 RAs are effective and safe for treating SICR and WGR after bariatric surgery.
Study Design & Sample: Meta-Analysis published in Obesity surgery (N = 1290 human participants).
Biostatistical Rigor Score: 94/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Obesity surgery (2025), this meta-analysis evaluating 1,290 human participants investigated: Suboptimal initial clinical response (SICR) and weight gain recurrence (WGR) are challenging issues following bariatric surgery. Key clinical takeaway: GLP-1 RAs are effective and safe for treating SICR and WGR after bariatric surgery.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Obesity surgery, 2025-03-15; N = 1290; Rigor 94/100): GLP-1 RAs are effective and safe for treating SICR and WGR after bariatric surgery.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: liraglutide → Rx: tirzepatide → Rx: semaglutide → Rx: oral-semaglutide → Condition: surgery → Condition: bone-disease-metabolic → Condition: localized-adiposity →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 39948306: Meta-Analysis: Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery (N = 1,290)

3 of 3 Free Questions Remaining